A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STOP-CO
- 16 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Aug 2016 Status changed from not yet recruiting to recruiting.